Diabetic Neuropathy Market Size, Share, Growth Analysis, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy), By Drug Class (Capsaicin, Opioid), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2024-2031

Due to the rise in R&D projects, Johnson & Johnson and GlaxoSmithKline plc are the major players outperforming the diabetic neuropathy market. Major market companies are being influenced by this to diversify their product offerings globally. As a result, the important companies' varied product portfolios tend to increase the company's value. For instance, The most significant player in the market is thought to be Pfizer Inc. due to its emphasis on creating goods like Motrin and Lyrica that are expected to fuel growth.

Diabetic Neuropathy Market Top Players Company Profiles

• Abbott Laboratories 
• Eli Lilly and Company 
• Pfizer Inc. 
• F. Hoffmann-La Roche Ltd. 
• GlaxoSmithKline plc 
• Lupin Pharmaceuticals, Inc. 
• Astellas Pharma US, Inc. 
• Bayer AG 
• Teva Pharmaceutical Industries Ltd. 
• NeuroMetrix Inc. 
• Helixmith Co., Ltd. 
• Johnson & Johnson Services, Inc. 
• Daiichi Sankyo Company, Limited 
• Ionis Pharmaceuticals, Inc. 
• Akcea Therapeutics, Inc. 
• Alfasigma USA, Inc. 
• ExeGi Pharma LLC 

Diabetic Neuropathy Market Recent Development

• In January 2022, FDA approved Spinal cord stimulation therapy, according to Medtronic, for the treatment of persistent pain brought on by diabetic peripheral neuropathy.
• In December 2021, in order to develop "Ask your Doctor," the pharma business P&G Health, with its headquarters in India, collaborated with the English-language local newspaper Hindustan Times. The purpose of this online event is to inform the public about diabetic neuropathy and how to treat it.